What Does WTO Extension For LDCs To Enforce IP Mean For Pharmaceuticals? 02/08/2013 by Catherine Saez, Intellectual Property Watch 2 Comments The recent extension granted by World Trade Organization members to least developed countries giving 8 more years to implement international intellectual property protection rules threw a shroud of confusion over a parallel WTO waiver for pharmaceutical products conferred on least developed countries until 2016. In an attempt to shed some light on the issue, several experts were asked for their reflections on the consequences of the new extension.
International Coalition Counters TPP Secrecy With Open Copyright Forum 01/08/2013 by Intellectual Property Watch Leave a Comment A coalition of international public interest and business organisations has launched an open, crowdsourced platform to discuss what copyright should look like under the Trans-Pacific Partnership (TPP) agreement.
Governments Disagree On GI Protection At TLD Level 01/08/2013 by Monika Ermert for Intellectual Property Watch 1 Comment Governments met recently to try to decide: Should special protection be provided online for geographical indications, in addition to trademark rights, geographical names and names of international organisations?
Infojustice: The Question Of Patent Eligible Subject Matter And Evergreening Practices 31/07/2013 by Intellectual Property Watch Leave a Comment Infojustice writes: Over the past few years, patent-eligible subject matter has become one of the hotly debated areas of patent law in several countries. Even in the United States, the Supreme Court is beginning to express concerns about overly inclusive patent rules that stifle both competition and follow-on innovation. However, significant confusion persists over the difference between patent eligible subject matter and patentability requirements. Patent eligibility tests have proven quite difficult to apply, often leading to inconsistent and unpredictable results.
EFPIA, PhRMA Release Joint Principles For Clinical Trial Data-Sharing, To Criticism 30/07/2013 by Intellectual Property Watch 1 Comment The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) endorsed joint principles for clinical trial data-sharing.
Infojustice: Setting The Record Straight On Fair Use In US 30/07/2013 by Intellectual Property Watch Leave a Comment A paper examining the fair use doctrine in the United States, published by law professors Peter Jaszi and Matthew Sag and University of California at Berkeley fellow Gwen Hinze, addresses specific issues raised in an earlier submission to the Australian Law Reform Commission (ALRC) by the Kernochan Center for Law, Media and the Arts.
Patent Risk: The ‘New Normal’ In Patent Troll Litigation 30/07/2013 by Kelly Burke for Intellectual Property Watch Leave a Comment New York – Financial companies in 2012 faced nearly four times the patent litigation from non-practicing entities (NPEs), often called “patent trolls”, than they did five years ago and 2013 promises to be no different, according to a presentation by RPX Corporation, a patent risk management services provider. Financial institutions’ use of social media and its associated risk was also a topic of discussion.
IP And Public Health, Biotech Rise As Issues In TPP Negotiations 30/07/2013 by Brittany Ngo for Intellectual Property Watch 3 Comments Intellectual property and the issues of biotechnology and public health are rising concerns for stakeholders to the Trans-Pacific Partnership agreement negotiations.
European Commission Proposes Rules Changes To Create Unitary Patent Court 29/07/2013 by Intellectual Property Watch 3 Comments The final legislative piece needed for the establishment of a unitary EU patent system emerged from the European Commission today.
United States Confounded By Standard-Essential Patents 29/07/2013 by Steven Seidenberg for Intellectual Property Watch 2 Comments The United States is in a muddle over standard-essential patents. The nation’s courts and its executive agencies all agree that these patents play vital roles in the economy, but they disagree about what remedies are available when these patents are infringed. A recent decision by the US International Trade Commission has added to the confusion.